 |
 |
LATEST
Uptake Medical Announces First Patients Treated in Clinical Trial for Patients with Heterogeneous Emphysema (the VAPOR trial) Seattle, WA – December 21, 2009. Uptake Medical Corp., a developer of medical technologies for the non-surgical treatment of lung diseases including emphysema, announced today that the first patients were treated in its Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction in Patients Diagnosed with Heterogeneous Emphysema with Upper Lobe Predominance (VAPOR) trial. The successful treatment of the first two patients in the VAPOR trial occurred on December 17th, 2009 at the Alfred Hospital in Melbourne, Australia. The procedure was performed by Dr. Gregory Snell, Dr. Trevor Williams and the Alfred Hospital team and attended by Founder and CTO Robert Barry. “We continue to be impressed not only with the ease and simplicity of the procedure, but the excellence of the sites participating in this study. The Alfred team continues to lead the way in clinical studies aimed at helping emphysema sufferers,” Barry said. The VAPOR trial is a multi-national study designed to collect data to support CE Mark approval. It is being conducted at sites in Australia and Europe. “We are happy to be starting off this trial since we continue to view BTVA as a potential option for patients suffering with severe emphysema based on our experience with earlier BTVA trials. BTVA holds the promise of a safe, simple and effective bronchoscopic approach to lung volume reduction for many patients who have limited treatment options,” stated Gregory Snell, MD. The VAPOR trial is based on the company’s earlier trial that showed the potential of the BTVA technology to improve the lives of patients suffering with emphysema. In the preceding trial, patients who responded to the treatment demonstrated a clinically meaningful improvement in FEV1 an important pulmonary function measure. Additionally, the average improvement in quality of life as measured by the St. Georges Respiratory Questionnaire was more than double the 4 point clinically meaningful improvement standard. The subjects completed the 6-month follow-up with an acceptable safety profile. Bronchoscopic Thermal Vapor Ablation (BTVA) is a non-surgical bronchoscopic procedure that helps patients with emphysema breathe easier. BTVA achieves lung volume reduction by delivering thermal vapor through a catheter which causes the diseased portion of the lung to gradually reduce in volume. This non-surgical lung volume reduction allows the remaining healthy lung to expand more fully and function more normally. "We are looking forward to initiating enrollment in all centers and generating a significant pool of clinical data upon which to build our CE Mark submission. We are working with leading centers in Australia and Europe and hope to conclude enrollment early in 2010,” said King Nelson, President and CEO. Uptake Medical is also initiating Phase I clinical trials in the United States with enrollment commencing in early 2010. About Uptake Medical Uptake Medical™ Corp. is a developer of medical technologies for the treatment of lung diseases including emphysema. The core technology is a simple, minimally invasive, non-implant interventional pulmonary approach designed to measurably improve lung function and patient quality of life. Emphysema afflicts over 4 million people in the United States. For more information and a list of participating clinical trial sites, please visit www.uptakemedical.com. RECENT NEWS Uptake Medical Presents Data from Safety & Feasibility Clinical Trial for Patients |
|
| The Bronchoscopic Thermal Vapor Ablation System (BTVA) is investigational and not approved for use in the United States or abroad. |
|
||
| ©2010 Uptake Medical™ |